IL6 and liver cancer: Attia et al. observed that, in HepG2, Huh7, and SNU-449 liver cancer cell lines, by targeting and activating FXR receptor, OCA inhibits the JAK2-STAT3 signaling pathway, downregulates the expression of the suppressor of cytokine signaling-3 (SOCS3), and consequently reduces the production and expression of cytokine interleukin-1β (IL-1β) and cytokine interleukin-6 (IL-6), effectively blocking the dissemination and progression of liver cancer [94].